COMMUNIQUÉS West-GlobeNewswire

Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019

06/03/2019 - 14:30

ROCHESTER, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases [...]

Homology Medicines to Present at Cowen Healthcare Conference

06/03/2019 - 14:30

BEDFORD, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present at the Cowen and Company 39th Annual [...]

PSIQ Files Amendment # 1 to Form S-1 as the Next Step to Becoming an SEC Reporting Issuer and Uplisting to OTCQB

06/03/2019 - 14:30

SUNRISE, Fla., March 06, 2019 (GLOBE NEWSWIRE) -- Profile Solutions, Inc. (OTC Pink: PSIQ) is pleased to announce the filing of amendment # 1 to the Registration Statement on Form S-1 with the U.S. Securities and [...]

Evoke Pharma Reports Fourth Quarter and Full Year 2018 Financial Results and FDA Communication

06/03/2019 - 14:30

Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration (FDA) for Gimoti™ 505(b)(2) New Drug Application (NDA) April 1, 2019 Prescription Drug User Fee Act (PDUFA) date maintained [...]

Exactus Places $1 Million Purchase Order for CBD Products to Accelerate Near Term Growth

06/03/2019 - 14:27

GLEN ALLEN, Va., March 06, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB: EXDI) , a healthcare company pursuing opportunities in Hemp derived Cannabidiol (CBD) products, today announced it had placed an initial purchase [...]

Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering

06/03/2019 - 14:25

OCALA, Fla., March 06, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) (“Hemispherx” or the “Company”), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical [...]

SATO America Launches the New Standard in Healthcare Printing Solutions

06/03/2019 - 14:22

CHARLOTTE, N.C., March 06, 2019 (GLOBE NEWSWIRE) -- SATO America, a leading provider of barcode and RFID application solutions has launched the WS2 direct thermal desktop printer. Setting the new standard in 2-inch [...]

Genocea to Present at the Cowen & Company 39th Annual Health Care Conference

06/03/2019 - 14:05

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip Clark, president and [...]

Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders

06/03/2019 - 14:03

NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written [...]

Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants

06/03/2019 - 14:02

Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCROSS, Ga., March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of [...]

Arise Austin Medical Center and The Hospital at Westlake Medical Center select Allscripts Sunrise

06/03/2019 - 14:01

Texas organizations choose Allscripts Sunrise™ for robust EHR with a single patient record CHICAGO, March 06, 2019 (GLOBE NEWSWIRE) -- Arise Austin Medical Center, located in Austin, TX and The Hospital at Westlake [...]

Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update

06/03/2019 - 14:00

Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga., March 06, 2019 (GLOBE [...]

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

06/03/2019 - 14:00

Interim Data Update from Phase 2 Study Demonstrates Meaningful Clinical Improvement with Excellent Patient Safety Profile Company Provides Clinical Development Plan with Pathways to Registration HOUSTON, March 06, 2019 [...]

Tabula Rasa HealthCare Appoints New Member to its Board of Directors

06/03/2019 - 14:00

Rear Admiral Pamela Schweitzer, PharmD Joins Board of Medication Safety Company MOORESTOWN, N.J., March 06, 2019 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC) , a healthcare technology company [...]

Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine

06/03/2019 - 14:00

WESTMINSTER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for [...]

IRIDEX to Present at the 31st Annual Roth Conference

06/03/2019 - 14:00

MOUNTAIN VIEW, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the Company plans to present at the upcoming 31 st Annual Roth Conference in Orange County, CA. Management is [...]

CymaBay Announces Pricing of Public Offering of Common Stock

06/03/2019 - 14:00

NEWARK, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients [...]

Immutep doses First Patient in TACTI-002 Phase II Trial

06/03/2019 - 14:00

The First Patient has been dosed at “START Madrid- FJD” in Spain Clinical trial sites are active and more will be activated and commence recruitment in coming months SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE [...]

Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference

06/03/2019 - 14:00

EVANSTON, Ill., March 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]